Valeritas +48% as study shows V-Go clinical benefits

|About: Valeritas Holdings, Inc. (VLRX)|By:, SA News Editor

Valeritas (NASDAQ:VLRX) +48.6% premarket after announcing positive results in a study of its V-Go wearable insulin delivery device in type 2 Diabetes patients who switched from insulin pens and syringes.

“The largest study of V-Go patients to date has demonstrated that regardless of baseline insulin dose or duration of diabetes, patients who switched to V-Go significantly lowered their blood glucose," the company says.

Subscribe for full text news in your inbox